Carboxymethyl dextran-cyclodextrin conjugate as the carrier of doxorubicin

J Nanosci Nanotechnol. 2013 Nov;13(11):7271-8. doi: 10.1166/jnn.2013.8091.

Abstract

The carboxymethyl dextran-y-cyclodextrin (CMD-yCD) conjugate was prepared as the carrier for the delivery of the poorly water-soluble anticancer drug, doxorubicin (DOX). The conjugate could form self-assembled nanoparticles (315 nm in diameter) in an aqueous solution, which might be due to the hydrogen bonding among yCD molecules in the conjugate. DOX was effectively encapsulated into CMD-yCD nanoparticles (CMD-NPs) by the emulsion method. In particular, regardless of the feed amount of DOX, its loading efficiencies were always greater than 70%. CMD-NPs released DOX in a sustained manner, owing to the inclusion complex formation between DOX and yCD. When Cy5.5-labeled CMD-NPs were treated with SCC7 cancer cells, strong fluorescence signals were observed at the cytosol, indicating effective intracellular uptake. In addition, DOX-loaded CMD-NPs exhibited dose-dependent cytotoxicity to SCC7 cancer cells. However, the empty nanoparticles did not show toxicity to the cells, implying their high biocompatibility. Overall, these results suggest that the CMD-gammaCD conjugate could be a useful carrier for the delivery of DOX.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / chemistry
  • Carcinoma, Squamous Cell / drug therapy*
  • Carcinoma, Squamous Cell / pathology*
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Diffusion
  • Doxorubicin / administration & dosage*
  • Doxorubicin / chemistry*
  • Mice
  • Nanocapsules / administration & dosage*
  • Nanocapsules / chemistry*
  • Nanocapsules / ultrastructure
  • Particle Size
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Nanocapsules
  • Doxorubicin